- Virtual ground-breaking of the expanded manufacturing facility of consumables;
- Strategic partnership with Zhifei Longcom Biologic Pharmacy to improve process of vaccine development;
- Accelerated collaboration with Clover Biopharmaceuticals to support the scale-up of its protein-based COVID-19 S-Trimer subunit vaccine candidate;
- Joint lab to be set up with Jinbo Bio-Pharmaceutical to advance industry innovation.
November 6, 2020
Cytiva, a global life sciences leader, entered four agreements during its debut at the Third China International Import Expo in Shanghai, underscoring the company’s commitment to bolster China’s biotechnology industry and foster a healthy local ecosystem.
In China’s most high-profile import-themed fair, Cytiva signed a string of deals with Wego, Zhifei, Clover and Jinbo, pledging to invest in fields of manufacturing, bioprocess development, and research to accelerate the development and manufacture of therapeutics and benefit patients in the country and beyond.
Yu Li Hua, General Manager of Cytiva Greater China, says: “China is one of Cytiva’s most important and fastest-growing markets. With deep roots and heritage in this country, we will continue to accelerate and advance therapeutics with our know-how and technical innovation. The collaboration with our local partners displays our long-term commitment to Chinese market, and shows how our ‘in China for China’ strategy could also benefit the broader Asia-Pacific region.”
Cytiva and Wego announced plans to triple the single-use manufacturing capacity in Asia Pacific to produce bags, components and other customized products. The expanded capacity also responds to surging needs from neighboring markets like Japan and South Korea.
Cytiva also contributes to advance and accelerate the production of various vaccines in China. A comprehensive strategic partnership with Zhifei allows the pair to work on process development, raw material supply, service and personnel training. Cytiva will facilitate Zhifei’s deployment of vaccines, therapeutic antibodies, cell therapy and other projects in the pipelines, accelerating clinical application and commercialization.
Under the upgraded partnership with Clover, Cytiva helps the global clinical stage biotechnology company add two more 2000L bioreactors for a total of 4 x 2000L manufacturing capacity through the Cytiva FlexFactory, which will provide a total solution including process equipment, services, and consumables to ensure safety, efficiency, scaled-up capacity for vaccine development.
Cytiva also commits to creating a “Joint Lab on Human Collagen New Material” with Jinbo. The tie-up, connecting Jinbo’s recombinant DNA technology and Cytiva’s capability to enable massive production of Human Collagen Type III, stands to tap into China’s booming medical cosmetology market.
Yu Li Hua adds: “Through multi-level cooperation and tangible projects, we forge closer ties with our partners. Our aim is always to provide more accessible technology and products to our customers and patients, and no one can do it alone.”
For more information about Cytiva’s global capacity expansion plan, click here.
For more information about Cytiva's efforts to address COVID-19, click here.
About Cytiva
Cytiva is a global life sciences leader with more than 7,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
Media Contact:
Iris Zhao
[email protected]
+86 185 0212 7884